Magdalena Krintus
Overview
Explore the profile of Magdalena Krintus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panteghini M, Krintus M
Crit Rev Clin Lab Sci
. 2025 Jan;
:1-34.
PMID: 39743528
Poor analytical quality may be the bane of medical use of laboratory tests, and the fight against excessive analytical variability presents a daily struggle. Laboratories should prioritize the perspectives and...
2.
Bergmann K, Stefanska A, Kubica J, Krintus M, Panteghini M
J Clin Med
. 2024 Dec;
13(23).
PMID: 39685587
Low but detectable cardiac troponin (cTn) concentrations may reflect cardiovascular (CV) risk in a primary prevention setting. Using previously described thresholds for CV risk stratification, we assessed the influence of...
3.
Szternel L, Sobucki B, Wieprzycka L, Krintus M, Panteghini M
Clin Chim Acta
. 2024 Oct;
565:119999.
PMID: 39401651
Golgi protein 73 (GP73) is implicated in key pathogenic processes, particularly those related to inflammation and fibrogenesis. In the last years, its measurement has emerged as a promising biomarker for...
4.
Stefanska A, Krintus M, Siodmiak J, Wolska A, Szternel L, Gackowska L, et al.
Clin Chem Lab Med
. 2024 Oct;
63(4):e104-e107.
PMID: 39377213
No abstract available.
5.
Ratajczak J, Kubica A, Pietrzykowski L, Michalski P, Kosobucka-Ozdoba A, Buczkowski K, et al.
J Clin Med
. 2024 Aug;
13(16).
PMID: 39200791
: Elevated lipoprotein (a) [Lp(a)] concentrations are linked mainly to genetic factors. The relationship between Lp(a) and other lipid disorders or cardiovascular (CV) risk factors has been less investigated. The...
6.
Gajewski P, Krintus M, Chudas K, Pawlowski R, Laskowska E, Jasiewicz M, et al.
EJIFCC
. 2024 May;
35(1):10-22.
PMID: 38706733
Background: BD Barricor tubes have been proposed to decrease laboratory turnaround time (TAT). We analytically validated and then clinically verified these tubes for use with Abbott Alinity and Siemens Atellica...
7.
Stefanska A, Bergmann K, Suwala S, Mankowska-Cyl A, Kozinski M, Junik R, et al.
Metabolites
. 2024 Jan;
14(1).
PMID: 38248855
Metabolic dysfunction-associated fatty liver disease (MAFLD) may progress to advanced liver fibrosis (ALF). We evaluated the diagnostic accuracy of a novel Liver Fibrosis Risk Index (LFRI) in MAFLD subjects using...
8.
Suwala S, Bialczyk A, Koperska K, Rajewska A, Krintus M, Junik R
J Clin Med
. 2023 Dec;
12(24).
PMID: 38137829
Diabetes and obesity have been recognized as confirmed risk factors for the occurrence of liver fibrosis. Despite the long-standing acknowledgment of "diabesity", the simultaneous existence of diabetes and obesity, scholarly...
9.
Kloska S, Kozinski M, Stefanska A, Bergmann K, Mankowska-Cyl A, Siodmiak J, et al.
J Med Biochem
. 2023 Dec;
42(4):665-674.
PMID: 38084246
Background: Cardiac myosin-binding protein C (cMyC) is a novel cardio-specific biomarker of potential diagnostic and prognostic value for cardiovascular events. This study aims to determine reference values for cMyC and...
10.
Bergmann K, Stefanska A, Krintus M, Szternel L, Bilinski W, Paradowski P, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630857
Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD)-a new definition for non-alcoholic fatty liver disease-reflects the impact of metabolic abnormalities on liver function. We assessed the diagnostic accuracy of biomarker-based scores...